Zacharon is leveraging its proprietary glycan-targeted drug discovery engine to create a pipeline of novel small molecule therapeutics for many diseases where glycans are strongly implicated in disease pathogenesis. The following table illustrates the company’s more advanced programs.

For more information about Zacharon’s therapeutic program for the Mucopolysaccharidoses (MPS), please click HERE.

Zacharon also has developed an innovative clinical diagnostic for lysosomal storage disease. For more information about this program, please click HERE.